ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0105

Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients

Balázs Juhász1, Katalin Gulyás1, Ágnes Horváth1, Edit Végh1, Anita Pusztai2, Ágnes Szentpétery3, Zsófia Pethő1, Nóra Bodnár1, Attila Hamar1, Levente Bodoki1, Harjit Bhattoa1, Éva Szekanecz1, Katalin Hodosi1, Andrea Domján1, Szilvia Szamosi1, Csaba Horváth4, Sándor Szántó1, Gabriella Szűcs1, Hennie Raterman5, Oliver FitzGerald6 and Zoltán Szekanecz1, 1University of Debrecen, Debrecen, Hungary, 2University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, 3Uppsala University Hospital, Uppsala, Sweden, 4Semmelweis University, Budapest, Hungary, 5Northwest Clinics, Alkmaar, Netherlands, 6Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland

Meeting: ACR Convergence 2020

Keywords: osteoporosis, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Session Title: Osteoporosis & Metabolic Bone Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have both been associated with generalized and localized bone loss. Inflammatory cytokines like tumor necrosis factor (TNF) have been implicated in bone resorption and, therefore, anti-TNF biologics may improve bone status. There have been very few observational or longitudinal data on the use of peripheral quantitative computed tomography (QCT) for determining changes in bone status in anti-TNF-treated RA and AS patients. Therefore, we assessed volumetric bone mineral density (BMD) by forearm QCT in conjunction with disease activity, dual-energy X-ray absorptiometry (DXA) and bone biomarker parameters in a mixed cohort of RA and AS patients.

Methods: Fifty-three consecutive patients including 36 RA patients treated with etanercept (ETN) or certolizumab pegol (CZP) and 17 AS patients treated with ETN were included in a 12-month follow-up study. Volumetric (3-dimensional) and areal (2-dimensional) BMD were determined by peripheral QCT and DXA, respectively. Bone biomarkers, such as calcium, phosphate, PTH, osteocalcin, soluble RANKL, vitamin D3, P1NP, CTX, sclerostin, DKK-1 and cathepsin K (CATHK) were assessed by ELISA. DAS28 and BASDAI served as markers of disease activity in RA and AS, respectively. Determinants of volumetric BMD were investigated by uni- and multivariable regression analyses, as well as RM-ANOVA.

Results: One-year ETN or CZP therapy arrested further progression of bone loss in the radius in RA and AS as determined by peripheral QCT. Volumetric (QCT) and areal (DXA) BMD showed significant, variable correlations with each other (p< 0.05). The univariable analysis showed that total QCT BMD after 12 months was inversely determined by disease activity at baseline (p=0.030). Cortical BMD was negatively determined by baseline disease activity (p=0.005), as well as baseline (p=0.025) and 12-month CATHK levels (p=0.033). The negative associations of 12-month total (p=0.030) and cortical BMD (p=0.012) with baseline disease activity was also confirmed by multivariable analysis. The change in QCT trabecular BMD between baseline and 12 months was related to the anti-TNF treatment together with higher baseline vitamin D3 levels (VITD3-0) (p=0.031). In addition, TNF inhibition and lower cathepsin K determined cortical BMD changes over the one-year period (p=0.006).

Conclusion: QCT may be a suitable methodology to measure volumetric BMD in various compartments (trabecular and cortical) of the radius. QCT confirmed that biologics may arrest generalized bone loss. Moreover, we identified baseline parameters, such as disease activity, CATHK and possibly VITD3 that may predict the effects of one-year anti-TNF treatment on volumetric BMD changes over time.


Disclosure: B. Juhász, None; K. Gulyás, None; �. Horváth, None; E. Végh, None; A. Pusztai, None; �. Szentpétery, None; Z. Pethő, None; N. Bodnár, None; A. Hamar, None; L. Bodoki, None; H. Bhattoa, None; �. Szekanecz, None; K. Hodosi, None; A. Domján, None; S. Szamosi, None; C. Horváth, None; S. Szántó, None; G. Szűcs, None; H. Raterman, None; O. FitzGerald, AbbVie Inc., 2, 5, Amgen, 2, 5, Bristol Myers Squibb, 2, 5, Celgene, 2, 5, Janssen, 2, 5, Eli Llilly, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, UCB, 2, 5; Z. Szekanecz, Pfizer, 1.

To cite this abstract in AMA style:

Juhász B, Gulyás K, Horváth �, Végh E, Pusztai A, Szentpétery �, Pethő Z, Bodnár N, Hamar A, Bodoki L, Bhattoa H, Szekanecz �, Hodosi K, Domján A, Szamosi S, Horváth C, Szántó S, Szűcs G, Raterman H, FitzGerald O, Szekanecz Z. Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/use-of-peripheral-quantitative-computed-tomography-in-the-assessment-of-bone-mineral-density-in-anti-tnf-treated-rheumatoid-arthritis-and-ankylosing-spondylitis-patients/. Accessed July 3, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-peripheral-quantitative-computed-tomography-in-the-assessment-of-bone-mineral-density-in-anti-tnf-treated-rheumatoid-arthritis-and-ankylosing-spondylitis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies